These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37499870)

  • 1. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Tarantino P; Tolaney SM; Curigliano G
    Ann Oncol; 2023 Oct; 34(10):949-950. PubMed ID: 37499870
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Wei T; Wang D; Yuan P
    Ann Oncol; 2023 Oct; 34(10):948-949. PubMed ID: 37499869
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.
    Cancer Discov; 2020 Apr; 10(4):488. PubMed ID: 32111601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
    Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
    Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-DXd: New Standard for HER2-Low Breast Cancer.
    Cancer Discov; 2022 Aug; 12(8):1828. PubMed ID: 35666611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
    Rolfo C; Del Re M; Russo A
    Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
    Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
    Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
    Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
    Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).
    Med Lett Drugs Ther; 2020 Nov; 62(1611):182-184. PubMed ID: 33429416
    [No Abstract]   [Full Text] [Related]  

  • 16. Using Trastuzumab Deruxtecan to treat advanced metastatic breast cancer in patients with varying HER2 expression levels: A single-center experience in Taiwan.
    Wu CW; Cheng FT
    Medicine (Baltimore); 2024 Jul; 103(28):e38911. PubMed ID: 38996157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-DXd Keeps Shining in Breast Cancer.
    Cancer Discov; 2023 Feb; 13(2):254. PubMed ID: 36484540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.
    Tarantino P; Curigliano G; Tolaney SM
    Cancer Discov; 2022 Sep; 12(9):2026-2030. PubMed ID: 35856622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.